Doc, I don't think L is a threat to BP. All the trials working to improve the results of L include other treatments from BP. The trial - at least for nGBM- was in addition to soc, not a replacement. Not as clear for direct. We do know that those on direct had one or more other treatments before trying direct so could it have been additive or from direct alone. We needed all those other direct trials they talked about for years. Also, would like to hear an update on direct that Bosch spoke of years back - are there still survivors, if so that would be remarkable or are they all gone
Market Data 
Markets 
AI
